Johnson Lee, Malone Marc, Paulson Erik, Swider Josh, Marelius David, Andersen Susan, Black Dominic
CBD Oracle, 17291 Irvine Blvd, Tustin, CA, 92780, USA.
Infinite Chemical Analysis Labs, 8312 Miramar Mall, San Diego, CA, 92121, USA.
J Cannabis Res. 2023 Jul 26;5(1):29. doi: 10.1186/s42238-023-00197-6.
Hemp-derived delta-9 tetrahydrocannabinol (∆ THC) products are freely available for sale across much of the USA, but the federal legislation allowing their sale places only minimal requirements on companies. Products must contain no more than 0.3% ∆ THC by dry weight, but no limit is placed on overall dosage and there is no requirement that products are tested. However, some states-such as Colorado-specifically prohibit products created by "chemically modifying" a natural hemp component.
Fifty-three ∆ THC products were ordered and submitted to InfiniteCAL laboratory for analysis. The lab analysis considered potency, the presence of impurities, and whether the ∆ THC present was natural or converted from CBD. The presence of age verification, company-conducted testing, and warning labels was also considered.
While 96.2% of products were under the legal ∆9 THC limit, 66.0% differed from their stated dosage by more than 10%, and although 84.9% provided a lab report to customers, 71.1% of these did not check for impurities. Additionally, 49% of products converted CBD to THC to achieve their levels, and only 15.1% performed age verification at checkout.
Despite some positive findings, the results show that hemp ∆ THC companies offer inaccurately labeled products that contain more THC than would be allowed in adult-use states. This raises serious issues around consumer safety, and consent when consuming intoxicating products. Steps to boost accountability for companies must be considered by either the industry or lawmakers if intoxicating hemp products are to remain on the market safely.
源自大麻的δ-9四氢大麻酚（∆THC）产品在美国大部分地区均可自由销售，但允许其销售的联邦立法对公司仅提出了最低要求。产品的干重中∆THC含量不得超过0.3%，但对总剂量没有限制，也没有要求对产品进行检测。然而，一些州，如科罗拉多州，特别禁止通过“化学改性”天然大麻成分制成的产品。
订购了53种∆THC产品，并提交给InfiniteCAL实验室进行分析。实验室分析考虑了效力、杂质的存在以及所存在的∆THC是天然的还是由CBD转化而来的。还考虑了年龄验证、公司进行的检测以及警示标签的存在情况。
虽然96.2%的产品低于法定的∆9THC限量，但66.0%的产品与其标明的剂量相差超过10%，并且尽管84.9%的产品向客户提供了实验室报告，但其中71.1%并未检测杂质。此外，49%的产品将CBD转化为THC以达到其含量水平，只有15.1%在结账时进行了年龄验证。
尽管有一些积极的发现，但结果表明，大麻∆THC公司提供的产品标签不准确，所含THC比成人使用州允许的含量更多。这引发了围绕消费者安全以及消费致醉产品时的知情同意等严重问题。如果致醉性大麻产品要安全地留在市场上，行业或立法者必须考虑采取措施加强对公司的问责。
